Search Results

September 12, 2016

Johnson & Johnson Announces World Health Organization will Review Ebola Vaccine Regimen for Emergency Use Assessment and Listing (EUAL)

Preparations also underway to initiate first-in-human study for multivalent vaccine regimen to combat Ebola, Sudan and Marburg viruses

Innovative Medicine

August 22, 2016

For U.S. Media Only: Janssen Announces 25 Presentations at Upcoming ESC Congress 2016, Including New Clinical and Real-World Research on XARELTO® and Latest Findings from REVISIT-US

Innovative Medicine

August 16, 2016

Esketamine Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Major Depressive Disorder with Imminent Risk for Suicide

FDA action marks second Breakthrough Therapy Designation for intranasal esketamine, highlighting its potential as treatment for patients with major depressive disorder who are at imminent risk for suicide and for those with treatment-resistant depression

Innovative Medicine

July 26, 2016

Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer

Innovative Medicine

July 18, 2016

U.S. FDA Approves PREZISTA® (darunavir) for Use in Pregnant Women with HIV

Data shows PREZISTA® is a safe and effective treatment option in pregnant women, with no reports of mother-to-child HIV transmission among women who continued therapy through delivery

Global health equity

July 14, 2016

U.S. FDA Grants Priority Review to Janssen’s New Drug Application for Chewable Mebendazole Tablets Intended to Treat Soil-Transmitted Helminthiasis

Johnson & Johnson shows ongoing commitment to London Declaration on NTDs through advancement of new chewable tablet

Innovative Medicine

June 30, 2016

SIMPONI® Receives European Commission Approval for Treatment of Polyarticular Juvenile Idiopathic Arthritis

Health Authority Approval Marks Sixth Indication for SIMPONI in Europe

Innovative Medicine

June 29, 2016

Ibrutinib (IMBRUVICA®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for the Development of a Treatment for Chronic Graft-Versus-Host Disease (cGVHD)

- In current clinical practice, there are no FDA-approved treatments for this life-threatening condition - FDA designation suggests potential use of ibrutinib beyond hematologic malignancies - The FDA also granted ibrutinib orphan drug designation for cGVHD

Corporate

June 28, 2016

Johnson & Johnson Innovation and Janssen Research & Development Launch World Without Disease QuickFire Challenge

Largest QuickFire competition to date will award up to $500,000 in a research grant and entrance to Johnson & Johnson Innovation, JLABS, to promising transformational healthcare solution Challenge launched at 2016 BIO International Convention during the Bionic Innovation Forum

Search Results

Johnson & Johnson Announces World Health Organization will Review Ebola Vaccine Regimen for Emergency Use Assessment and Listing (EUAL)

For U.S. Media Only: Janssen Announces 25 Presentations at Upcoming ESC Congress 2016, Including New Clinical and Real-World Research on XARELTO® and Latest Findings from REVISIT-US

Esketamine Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Major Depressive Disorder with Imminent Risk for Suicide

Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer

U.S. FDA Approves PREZISTA® (darunavir) for Use in Pregnant Women with HIV

U.S. FDA Grants Priority Review to Janssen’s New Drug Application for Chewable Mebendazole Tablets Intended to Treat Soil-Transmitted Helminthiasis

SIMPONI® Receives European Commission Approval for Treatment of Polyarticular Juvenile Idiopathic Arthritis

Ibrutinib (IMBRUVICA®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for the Development of a Treatment for Chronic Graft-Versus-Host Disease (cGVHD)

Johnson & Johnson Innovation and Janssen Research & Development Launch World Without Disease QuickFire Challenge

Johnson & Johnson Teams Up With Health Officials Across Brazil to Fight Zika

You are now leaving jnj.com/innovativemedicine

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine